Deutsche Bank AG acquired a new stake in Gritstone Oncology Inc (NASDAQ:GRTS) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 29,056 shares of the company’s stock, valued at approximately $448,000. Deutsche Bank AG owned approximately 0.10% of Gritstone Oncology at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of GRTS. Citigroup Inc. acquired a new position in Gritstone Oncology in the 4th quarter valued at $28,000. Strs Ohio acquired a new stake in shares of Gritstone Oncology during the 4th quarter worth $29,000. American International Group Inc. acquired a new stake in shares of Gritstone Oncology during the 4th quarter worth $70,000. D. E. Shaw & Co. Inc. acquired a new stake in shares of Gritstone Oncology during the 4th quarter worth $157,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Gritstone Oncology during the 4th quarter worth $444,000. 48.83% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:GRTS traded down $0.14 during trading hours on Friday, hitting $9.83. The company’s stock had a trading volume of 102,433 shares, compared to its average volume of 187,720. The company has a quick ratio of 9.57, a current ratio of 9.57 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $354.88 million and a PE ratio of -1.35. Gritstone Oncology Inc has a twelve month low of $8.75 and a twelve month high of $32.90.
Gritstone Oncology (NASDAQ:GRTS) last posted its earnings results on Monday, May 13th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.03. The firm had revenue of $1.35 million during the quarter, compared to the consensus estimate of $1.20 million. On average, analysts anticipate that Gritstone Oncology Inc will post -2.39 EPS for the current fiscal year.
Several analysts have recently issued reports on GRTS shares. Zacks Investment Research raised Gritstone Oncology from a “sell” rating to a “hold” rating and set a $12.00 target price on the stock in a report on Tuesday, May 14th. HC Wainwright assumed coverage on Gritstone Oncology in a research note on Thursday, March 7th. They issued a “buy” rating and a $17.00 price objective on the stock. Raymond James assumed coverage on Gritstone Oncology in a research note on Thursday, March 14th. They issued an “outperform” rating and a $20.00 price objective on the stock. Cowen reaffirmed a “buy” rating on shares of Gritstone Oncology in a research note on Monday, May 13th. Finally, Berenberg Bank assumed coverage on Gritstone Oncology in a research note on Wednesday, March 27th. They issued a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $20.50.
Gritstone Oncology Profile
Gritstone Oncology Inc, an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.
Further Reading: Stock Selection – What is cash flow?
Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.